AIMC Topic: Drug Discovery

Clear Filters Showing 371 to 380 of 1689 articles

Drugs from drugs: New chemical insights into a mature concept.

Drug discovery today
Developing new drugs from marketed ones is a well-established and successful approach in drug discovery. We offer a unified view of this field, focusing on the new chemical aspects of the involved approaches: (a) chemical transformation of the origin...

Advancing Anticancer Drug Discovery: Leveraging Metabolomics and Machine Learning for Mode of Action Prediction by Pattern Recognition.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
A bottleneck in the development of new anti-cancer drugs is the recognition of their mode of action (MoA). Metabolomics combined with machine learning allowed to predict MoAs of novel anti-proliferative drug candidates, focusing on human prostate can...

Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases.

Drug discovery today
Neurodegenerative diseases (NDs) pose serious healthcare challenges with limited therapeutic treatments and high social burdens. The integration of artificial intelligence (AI) into drug discovery has emerged as a promising approach to address these ...

Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
The advent of artificial intelligence (AI) has catalyzed a profound transformation in the pharmaceutical industry, ushering in a paradigm shift across various domains, including drug discovery, formulation development, manufacturing, quality control,...

Data-augmented machine learning scoring functions for virtual screening of YTHDF1 mA reader protein.

Computers in biology and medicine
Machine learning is rapidly advancing the drug discovery process, significantly enhancing speed and efficiency. Innovation in computer-aided drug design is primarily driven by structure- and ligand-based approaches. When the number of known inhibitor...

A deep drug prediction framework for viral infectious diseases using an optimizer-based ensemble of convolutional neural network: COVID-19 as a case study.

Molecular diversity
The SARS-CoV-2 outbreak highlights the persistent vulnerability of humanity to epidemics and emerging microbial threats, emphasizing the lack of time to develop disease-specific treatments. Therefore, it appears beneficial to utilize existing resourc...

Drug-Target Binding Affinity Prediction in a Continuous Latent Space Using Variational Autoencoders.

IEEE/ACM transactions on computational biology and bioinformatics
Accurate prediction of Drug-Target binding Affinity (DTA) is a daunting yet pivotal task in the sphere of drug discovery. Over the years, a plethora of deep learning-based DTA models have emerged, rendering promising results in predicting the binding...

Geometry-Augmented Molecular Representation Learning for Property Prediction.

IEEE/ACM transactions on computational biology and bioinformatics
Accurate molecular representation plays a crucial role in expediting the process of drug discovery. Graph neural networks (GNNs) have demonstrated robust capabilities in molecular representation learning, adept at capturing structural and spatial inf...

A deep learning framework combining molecular image and protein structural representations identifies candidate drugs for pain.

Cell reports methods
Artificial intelligence (AI) and deep learning technologies hold promise for identifying effective drugs for human diseases, including pain. Here, we present an interpretable deep-learning-based ligand image- and receptor's three-dimensional (3D)-str...

Traversing chemical space with active deep learning for low-data drug discovery.

Nature computational science
Deep learning is accelerating drug discovery. However, current approaches are often affected by limitations in the available data, in terms of either size or molecular diversity. Active deep learning has high potential for low-data drug discovery, as...